AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 156 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,886 | -40.6% | 157 | -32.0% | 0.00% | -100.0% |
| Q2 2023 | $6,542 | +199.8% | 231 | +143.2% | 0.00% | – |
| Q1 2023 | $2,182 | -47.8% | 95 | -36.2% | 0.00% | -100.0% |
| Q4 2022 | $4,184 | +39.5% | 149 | +33.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | +50.0% | 112 | +51.4% | 0.00% | – |
| Q2 2022 | $2,000 | – | 74 | +572.7% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 11 | -88.5% | 0.00% | – |
| Q4 2021 | $3,000 | -50.0% | 96 | -28.9% | 0.00% | -100.0% |
| Q3 2021 | $6,000 | -14.3% | 135 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $7,000 | 0.0% | 135 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $7,000 | +16.7% | 135 | 0.0% | 0.00% | +100.0% |
| Q4 2020 | $6,000 | -14.3% | 135 | -27.8% | 0.00% | -50.0% |
| Q3 2020 | $7,000 | -30.0% | 187 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $10,000 | +100.0% | 187 | +38.5% | 0.00% | +50.0% |
| Q1 2020 | $5,000 | -16.7% | 135 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $6,000 | – | 135 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |